Aarti Drugs Ltd

Net profit of Aarti Drugs rose 29.33% to Rs 45.28 crore in the quarter ended September 2025 as against Rs 35.01 crore during the previous quarter ended September 2024. Sales rose 9.10% to Rs 652.79 crore in the quarter ended September 2025 as against Rs 598.33 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales652.79598.33 9 OPM %12.9111.21 - PBDT76.6759.60 29 PBT60.4145.88 32 NP45.2835.01 29 Powered by Capital Market - Live

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 7 November 2025.Powered by Capital Market - Live

Aarti Drugs announced that the 40th Annual General Meeting(AGM) of the company will be held on 24 September 2025.Powered by Capital Market - Live

Profit before tax (PBT) rose 16.2% YoY to Rs 51.11 crore in Q1 June 2025. EBITDA jumped 12% to Rs 74.4 crore in Q1 FY26 compared with Rs 66.1 crore in Q1 FY25. EBITDA margin expanded by 70 bps to 12.6% in Q1 FY26 from 11.9% posted in Q1 FY25. On segmental front, the revenue from API stood at Rs 458.2 crore (up 4% YoY), formulations was at Rs 80.3 crore (up 14% YoY), specialty & chemicals stood at Rs 33.1 crore (up 24% YoY) and intermediaries & others stood at Rs 18.9 crore (up 22% YoY) during the period under review. Adhish Patil, CFO & COO, of Aarti Drugs, said, 'During Q1FY26 the Company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D. For FY26, we expect Capex at around Rs 150-200 crore. The company has started trial productions at its new greenfield manufacturing facility in Sayakha, Gujarat. This plant has been set up mainly for backward integration into anti-diabetic products and their intermediates, and is expected to largely serve internal requirements. This backward integration is a key strategic step that should help improve profit margins over time and reduce the risk of input costs volatility. This project will support internal requirements for our anti-diabetic product and choline chloride, contributing to backward integration, margin improvement, and supply chain de-risking. The new greenfield Salicylic Acid plant at Tarapur is progressing well and is expected to begin contributing to the company's financials from the third quarter onwards. The company is now focused on a calibrated ramp-up of operations, with a clear roadmap to scale production to over 800 tonnes per month and further expand the installed capacity to approximately 1,600 tonnes per month by the end of FY26. Recently, the USA government has announced high tariffs on pharmaceutical products and APIs imported from countries like China. This move is aimed at reducing their dependence on Chinese suppliers. This has the potential to reshape global supply chains. While this may disrupt sourcing patterns for several players, it also opens up new opportunities for Indian API manufacturers. The company, with a recently USFDA approved API facility and established manufacturing capabilities, is strategically positioned to meet this demand shift. The commissioning of new capacity at Sayakha and Tarapur supports this readiness and enhances the Company's ability to serve regulated export markets. Our formulation subsidiary has also got USFDA approval for its Oncology facility alongside we are on a path to develop and register new oncology dossiers across the globe which will drive the regulated market growth from FY27 onwards.' Aarti Drugs was established in the year 1984 and forms part of $6 Billion Aarti Group of Industries. The company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, speciality chemicals and produces formulations with its wholly-owned subsidiary-Pinnacle Life Science.Powered by Capital Market - Live

Net profit of Aarti Drugs rose 62.18% to Rs 53.91 crore in the quarter ended June 2025 as against Rs 33.24 crore during the previous quarter ended June 2024. Sales rose 6.33% to Rs 590.51 crore in the quarter ended June 2025 as against Rs 555.34 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales590.51555.34 6 OPM %12.5511.70 - PBDT65.8357.36 15 PBT51.1143.98 16 NP53.9133.24 62 Powered by Capital Market - Live

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 18 July 2025.Powered by Capital Market - Live

Net profit of Aarti Drugs rose 32.70% to Rs 62.86 crore in the quarter ended March 2025 as against Rs 47.37 crore during the previous quarter ended March 2024. Sales rose 9.16% to Rs 676.76 crore in the quarter ended March 2025 as against Rs 619.99 crore during the previous quarter ended March 2024. For the full year,net profit declined 1.90% to Rs 168.16 crore in the year ended March 2025 as against Rs 171.42 crore during the previous year ended March 2024. Sales declined 5.60% to Rs 2387.03 crore in the year ended March 2025 as against Rs 2528.58 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales676.76619.99 9 2387.032528.58 -6 OPM %13.7913.84 -12.0312.52 - PBDT86.0477.76 11 267.56286.97 -7 PBT71.1664.18 11 211.78235.52 -10 NP62.8647.37 33 168.16171.42 -2 Powered by Capital Market - Live

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 6 May 2025.Powered by Capital Market - Live

Aarti Drugs has received reaffirmation in credit rating at ICRA AA-; Stable/ ICRA A1+ for bank facilities aggregating Rs 1452.8 crore. Powered by Capital Market - Live

Revenue from operations declined 6.44% to Rs 568.50 crore in third quarter of FY25 as compared with Rs 607.61 crore posted same period a year ago. Profit before tax shed 1.53% to Rs 50.76 crore in the third quarter of FY25 as against Rs 51.55 crore recorded in the same quarter last year. EBITDA stood at Rs 62.3 crore in Q3 of FY25, down 13% from Rs 71.8 crore posted in the December 2023 quarter. EBITDA Margin to 11.2% in Q3 FY25 as against with 11.8% posted in Q3 FY24. During the quarter, revenue from API segment declined 5.2% YoY to Rs 460 crore, formulation business dropped 39.4% YoY to Rs 48 crore while specialty chemicals increased 7.6% YoY to Rs 33.8 crore and intermediaries & others jumped 46.3% YoY to Rs 14.8 crore while in Q3 FY25. On standalone basis, the company's net profit increased 21.85% to Rs 38.53 crore in Q3 FY25 as compared with Rs 31.62 crore in Q3 FY24. Revenue stood at Rs 525.91 crore in December 2024 quartre, down 2.58% YoY. The standalone business contributed approximately 91% to the consolidated revenue for the quarter. Around 64% of the revenues came from the domestic market and 36% from the exports market for third quarter of FY25 for a standalone business. Within the API business, the antibiotic therapeutic category contributed around 38.6%, anti-diabetic approximately 16.1%, anti-protozoal around 16.5%, anti-inflammatory approximately 11.9%, antifungal around 12% and the rest contributed approximately 5% to total API sales for Q3 FY25. Meanwhile, the company's board has declared an interim dividend of Re 1 per equity share for the financial year 2023-24. The record date for the purpose of payment of interim dividend has been fixed as 4 February 2025. Adhish Patil, CFO & COO, Aarti Drugs, said, 'This quarter has presented significant challenges for our API segment, with both revenue and profit declining on a year-on-year basis. This is mainly due to reduced market prices and weaker demand. Although prices remained stable during the December quarter, there was a negative price variance when compared to the same period last year. Formulation segment revenue stood at Rs. 48.6 crores for the quarter, with an export contribution of 47% whereas in 9M FY25 revenue stood at Rs 186.9 crores. The greenfield project at Sayakha, Gujarat for Speciality Chemicals will commence trial production in this quarter. With this, the operating leverage is expected to kick in from the subsequent quarter with improved capacity utilization. There had been certain teething issues in Tarapur greenfield project, which are sorted now and we expect to ramp up the production to 500+ tonnes per month by the end of March'25. In total we will have sequential ramp up of capacity to 1,600 tonnes per month by end of FY26. During 9M FY25, the company has incurred capex of approximately Rs 136 crore mainly towards capacity expansion, backward integration and new product launches. We anticipate a total capex of around Rs 200 crore for the full year. This capex would we mainly through internal accruals and partly through term loans. Despite facing these short-term challenges, we are staying focused on our long-term goals. We are confident about achieving double digit growth in revenues with EBITDA Margins of 13%-14% in FY26 which is a healthy indicator of our financial stability and operational efficiency. Despite API pricing pressures, driven by fluctuating raw material costs, heightened competition, and regulatory demands in global markets we remain committed to achieving growth and profitability by enhancing operational efficiencies and expanding our market presence. We are dedicated to tackling these challenges and emerging stronger in the future.' Aarti Drugs forms part of $6 Billion Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Speciality Chemicals and produces Formulations with its whollyowned subsidiary-Pinnacle Life Science Private. Powered by Capital Market - Live